OIS Retina Innovation Summit banner

Thomas M. Aaberg, Jr., MD, PhD

Retina Specialists of Michigan / CMO - Neurotech
Caroline Baumal

Caroline Baumal, MD

Apellis / New England Eye Center, Tufts Medical Center
Robert Bhisitkul

Robert B. Bhisitkul, MD, PhD

University of California San Francisco School of Medicine

Pierre Billardon

DORC International B.V.
David Boyer, MD Retina Vitreous Associates Medical Group

David Boyer, MD

Retina Vitreous Associates Medical Group  

Paul Bresge

Ray Therapeutics

Greg Butz

Bank of America Merrill Lynch

Thomas A. Ciulla, MD, MBA, FASRS

Viridian Therapeutics / Indiana University School of Medicine / Midwest Eye Institute

Eugene de Juan, MD

UCSF Department of Ophthalmology

Pravin U. Dugel, MD

Ocular Therapeutix
David Eichenbaum

David A. Eichenbaum, MD

Retina Vitreous Associates of Florida
David Esposito

David Esposito

ONL Therapeutics
Claire Gelfman

Claire Gelfman, PhD

Foundation Fighting Blindness

Shamika Gune, MD

Genentech

Paul Hallen

Alcon
Erin Henry

Erin Henry, PhD

NGM Biopharmaceuticals

Nancy Holekamp, MD

Pepose Vision Institute

Jean-Pierre Hubschman, MD

Stein Eye Institute at UCLA
Mark-Humayun

Mark S. Humayun, MD, PhD

University of Southern California Roski Eye Institute
Peter Kaiser, MD

Peter Kaiser, MD

Cole Eye Institute

Jerry Lee, MBA

Goldman Sachs
James Murrey

James C. Murray

ExSight Ventures
Aaron Nagiel

Aaron Nagiel, MD, PhD

Keck School of Medicine of USC
Firas M. Rahhal, MD

Firas Rahhal, MD

ExSight Ventures & Retina Vitreous Associates Medical Group

Robert Rothman, MD

InFocus Capital Partners / OCLI/Glaucoma Consultants of Long Island
Russ Trenary

Russell Trenary

Outlook Therapeutics

Glenn C. Yiu, MD, PhD

UC Davis Health Department of Ophthalmology & Vision Science